Rigel to Present at the J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. ET. CEO Raul Rodriguez will provide a comprehensive overview of the company.
Interested parties can access the live webcast on Rigel's website. Rigel focuses on novel small molecule drugs for various diseases, with its FDA-approved product TAVALISSE for chronic immune thrombocytopenia.
The company is also progressing in clinical trials for multiple conditions, including COVID-19 and autoimmune diseases.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET on Wednesday, January 12, 2022.
To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to developing, and commercializing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE), the United Kingdom, and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical trial (NCT03764618) for the treatment of warm autoimmune hemolytic anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with mild-to-moderate COVID-191; an NIH/NHLBI-funded Phase 3 ACTIV-4 Host Tissue Study (NCT04924660) for the treatment of COVID-19 in hospitalized patients on oxygen therapy, and a Phase 2 clinical trial (NCT04581954) for the treatment of COVID-19 being conducted by Imperial College London.
Rigel's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, Rigel has product candidates in development with partners BerGenBio ASA, and Daiichi Sankyo.
For further information, visit www.rigel.com or follow us on Twitter or LinkedIn.
Please see www.TAVALISSE.com for full Prescribing Information.
1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.
Contact:
For Investors & Media
Jodi Sievers – Rigel Pharmaceuticals
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jp-morgan-healthcare-conference-301457580.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What time is Rigel Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?
Who is presenting on behalf of Rigel Pharmaceuticals at the conference?
How can I access the webcast of Rigel Pharmaceuticals' presentation?
What is Rigel Pharmaceuticals known for?
What is TAVALISSE and what is it used for?
What clinical trials is Rigel Pharmaceuticals currently conducting?
